Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback